Fortis Healthcare Ltd
FHL was incorporated in February 1996. The company’s first healthcare facility became operational in Mohali, Punjab in 2001. It is a leading integrated healthcare service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Nepal, Dubai and Sri Lanka with 36 healthcare facilities with approximately 4,000 operational beds. [1]
Company controls its diagnostics business through its 57% owned subsidiary SRL Limited. It is amongst the largest private diagnostics chains. It has a presence in over 600 cities and towns, with an established strength of 415 laboratories, 8,200 direct clients and 1,400 Collection Centers. [2]
- Market Cap ₹ 50,171 Cr.
- Current Price ₹ 665
- High / Low ₹ 744 / 406
- Stock P/E 249
- Book Value ₹ 120
- Dividend Yield 0.15 %
- ROCE 2.41 %
- ROE 1.37 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 38.8%
Cons
- Stock is trading at 5.53 times its book value
- Company has a low return on equity of 0.69% over last 3 years.
- Earnings include an other income of Rs.175 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Part of Nifty Alpha 50 BSE Allcap BSE SmallCap Select Index BSE 150 MidCap Index BSE 250 LargeMidCap Index
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
353 | 369 | 611 | 612 | 645 | 659 | 656 | 702 | 633 | 863 | 1,053 | 1,181 | 1,365 | |
353 | 449 | 758 | 737 | 792 | 697 | 780 | 633 | 605 | 747 | 919 | 988 | 1,111 | |
Operating Profit | -0 | -80 | -148 | -125 | -146 | -38 | -123 | 69 | 28 | 116 | 134 | 193 | 254 |
OPM % | -0% | -22% | -24% | -20% | -23% | -6% | -19% | 10% | 4% | 13% | 13% | 16% | 19% |
189 | 229 | 220 | 166 | 165 | 70 | 522 | 809 | 248 | 118 | 197 | 236 | 175 | |
Interest | 134 | 91 | 81 | 65 | 106 | 64 | 192 | 160 | 141 | 130 | 106 | 82 | 78 |
Depreciation | 23 | 17 | 27 | 25 | 27 | 29 | 27 | 97 | 111 | 113 | 116 | 101 | 108 |
Profit before tax | 32 | 41 | -36 | -50 | -114 | -60 | 180 | 621 | 24 | -9 | 109 | 247 | 243 |
Tax % | 46% | 42% | -5% | -19% | -34% | 6% | 31% | 17% | 83% | 48% | 12% | 19% | |
17 | 24 | -34 | -40 | -75 | -64 | 123 | 513 | 4 | -13 | 96 | 199 | 174 | |
EPS in Rs | 0.43 | 0.52 | -0.73 | -0.87 | -1.44 | -1.23 | 1.63 | 6.80 | 0.06 | -0.18 | 1.27 | 2.64 | 2.31 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 78% | 38% |
Compounded Sales Growth | |
---|---|
10 Years: | 12% |
5 Years: | 12% |
3 Years: | 23% |
TTM: | 19% |
Compounded Profit Growth | |
---|---|
10 Years: | 24% |
5 Years: | 0% |
3 Years: | 80% |
TTM: | 163% |
Stock Price CAGR | |
---|---|
10 Years: | 15% |
5 Years: | 40% |
3 Years: | 35% |
1 Year: | 54% |
Return on Equity | |
---|---|
10 Years: | 1% |
5 Years: | 2% |
3 Years: | 1% |
Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 405 | 463 | 463 | 463 | 518 | 519 | 755 | 755 | 755 | 755 | 755 | 755 | 755 |
Reserves | 2,796 | 3,247 | 3,217 | 3,284 | 3,754 | 3,708 | 7,608 | 8,122 | 8,127 | 8,114 | 8,209 | 8,332 | 8,322 |
1,018 | 1,279 | 1,234 | 1,076 | 647 | 555 | 1,478 | 1,361 | 1,380 | 1,193 | 785 | 659 | 581 | |
259 | 171 | 246 | 215 | 242 | 234 | 279 | 343 | 320 | 365 | 620 | 640 | 729 | |
Total Liabilities | 4,478 | 5,160 | 5,159 | 5,039 | 5,161 | 5,016 | 10,120 | 10,581 | 10,582 | 10,426 | 10,369 | 10,387 | 10,388 |
118 | 146 | 190 | 172 | 186 | 203 | 180 | 906 | 853 | 770 | 492 | 467 | 668 | |
CWIP | 73 | 121 | 169 | 182 | 199 | 166 | 165 | 33 | 7 | 6 | 3 | 260 | 119 |
Investments | 2,406 | 2,795 | 2,411 | 2,428 | 3,603 | 3,658 | 8,310 | 8,153 | 8,898 | 8,845 | 8,848 | 8,834 | 8,754 |
1,882 | 2,097 | 2,389 | 2,257 | 1,174 | 989 | 1,466 | 1,489 | 824 | 804 | 1,027 | 825 | 848 | |
Total Assets | 4,478 | 5,160 | 5,159 | 5,039 | 5,161 | 5,016 | 10,120 | 10,581 | 10,582 | 10,426 | 10,369 | 10,387 | 10,388 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | -45 | -144 | -761 | 22 | -15 | -61 | 100 | 32 | 76 | 198 | 218 | |
312 | -521 | 294 | 394 | -72 | 245 | -4,688 | 810 | 28 | 238 | 205 | 44 | |
-219 | 484 | -170 | 370 | 45 | -292 | 4,792 | -972 | 6 | -320 | -395 | -245 | |
Net Cash Flow | 95 | -82 | -20 | 3 | -5 | -62 | 43 | -62 | 66 | -6 | 8 | 18 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 96 | 86 | 57 | 61 | 43 | 39 | 47 | 42 | 43 | 32 | 34 | 41 |
Inventory Days | 17 | 16 | 18 | 15 | 14 | 19 | 17 | 25 | 21 | 25 | 18 | 15 |
Days Payable | 170 | 172 | 240 | 289 | 340 | 392 | 542 | 525 | 520 | 494 | 572 | 608 |
Cash Conversion Cycle | -57 | -70 | -165 | -213 | -284 | -334 | -479 | -457 | -456 | -438 | -520 | -553 |
Working Capital Days | 525 | 1,283 | 354 | 84 | 44 | -23 | 19 | 7 | 45 | 25 | 32 | -29 |
ROCE % | 4% | 3% | 0% | 1% | -0% | 1% | 5% | 9% | 1% | 1% | 2% | 2% |
Documents
Announcements
-
Compliances-Half Yearly Report (SEBI Circular No. CIR/IMD/DF-1/67/2017)
10 Apr - Reporting of debt securities issued through private placement.
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015.
3 Apr - Income tax demand order of Rs.76.19 Crore received.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
3 Apr - Certificate under Regulation 74(5) for Q1 2025.
-
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
2 Apr - Fortis Healthcare confirms acquisition of trademarks for INR 200 crores.
-
Disclosure Under Regulation 30 Of SEBI (LODR) - Regarding Fortis Trademarks And Allied Trademarks.
2 Apr - Fortis Healthcare confirmed acquisition of trademarks for INR 200 crores.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
Concalls
-
Feb 2025TranscriptPPT
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
May 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024TranscriptPPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Nov 2023TranscriptNotesPPT
-
Aug 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
May 2022TranscriptPPT
-
May 2022TranscriptPPT
-
Aug 2021TranscriptNotesPPT
-
May 2021TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Jun 2019TranscriptPPT
-
Feb 2019TranscriptNotesPPT
-
Jul 2018TranscriptPPT
-
Jun 2018TranscriptNotesPPT
-
Mar 2018TranscriptNotesPPT
-
Aug 2017TranscriptNotesPPT
-
May 2017TranscriptNotesPPT
-
Feb 2017TranscriptNotesPPT
-
Aug 2016TranscriptNotesPPT
-
May 2016TranscriptNotesPPT
-
Feb 2016TranscriptNotesPPT
Business Segments [1]
a) Hospital Segment: Co. operates Multi-specialty and super-speciality hospitals providing inpatient and outpatient treatments across various disciplines.